Factors associated with acute-phase response of bisphosphonate-na ïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate

ConclusionsIn a real-world setting, APR rates with ZOL and IBN may be higher than reported in randomised controlled trials and may differ by compound, prior BP exposure, and serum 25(OH)D levels.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research